Ram-Kumar A, Rajagopal K, Meenambiga SS, Kumaresan S. In vitro and in silico anti-breast cancer analysis of bioactive metabolites of bacillus subtilis isolated from soil. Saudi J Pathol Microbiol. 2020;05(4):220–9. https://doi.org/10.36348/sjpm.2020.v05i04.006.

Article  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.

Article  PubMed  Google Scholar 

Foletto MC, Haas SE. Cutaneous melanoma: new advances in treatment. An Bras Dermatol. 2014;89(2):301–10. https://doi.org/10.1590/abd1806-4841.20142540.

Article  PubMed  PubMed Central  Google Scholar 

Passarelli A, Mannavola F, Stucci LS, Tucci M, Silvestris F. Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget 2017;8(62):106132 [Online]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739707/.

Leonardi G, Candido S, Falzone L, Spandidos D, Libra M. Cutaneous melanoma and the immunotherapy revolution. Int J Oncol. 2020;57(3):609–18. https://doi.org/10.3892/ijo.2020.5088 (Review).

CAS  Article  PubMed  PubMed Central  Google Scholar 

Faramarzi S, Ghafouri-Fard S. Melanoma: a prototype of cancer-testis antigen-expressing malignancies. Immunotherapy 2017; 9(13):1103–13 [Online]. https://www.futuremedicine.com/doi/abs/10.2217/imt-2017-0091.

Candido S et al. Analysis of the B-RafV600E mutation in cutaneous melanoma patients with occupational sun exposure. Oncol Rep 2014;31(3):1079–82 [Online]. https://www.spandidos-publications.com/or/31/3/1079.

Lee N, Zakka N, Mihm Jr MC, Schatton T. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology 2016;48(2):177–87 [Online]. https://www.sciencedirect.com/science/article/pii/S0031302515000331.

Sullivan RJ, et al. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018;6(1):44. https://doi.org/10.1186/s40425-018-0362-6.

Article  PubMed  PubMed Central  Google Scholar 

Ralli M, et al. Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions. J Immunol Res. 2020;2020:1–12. https://doi.org/10.1155/2020/9235638.

CAS  Article  Google Scholar 

Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol 2014;192(12):5451–8 [Online]. https://www.jimmunol.org/content/192/12/5451.short.

Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon- for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003;29(4):241–52 [Online]. https://www.sciencedirect.com/science/article/pii/S0305737203000744.

Schwartzentruber DJ, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119–27.

CAS  Article  Google Scholar 

Rohaan MW, van den Berg JH, Kvistborg P, Haanen JBAG. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. J Immunother Cancer 2018;6(1):1–16 [Online]. https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0391-1.

Siegel R, Miller K, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. https://doi.org/10.3322/caac.21387.

Article  PubMed  Google Scholar 

Karimkhani C, et al. The global burden of melanoma: results from the Global Burden of Disease Study 2015. Br J Dermatol. 2017;177(1):134–40. https://doi.org/10.1111/bjd.15510.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Ali Z, Yousaf N, Larkin J. Melanoma epidemiology, biology and prognosis. Eur J Cancer Suppl. 2013;11(2):81–91. https://doi.org/10.1016/j.ejcsup.2013.07.012.

CAS  Article  Google Scholar 

Fitzmaurice C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990–2015. JAMA Oncol. 2017;3(4):524. https://doi.org/10.1001/jamaoncol.2016.5688.

Article  PubMed  Google Scholar 

Erdmann F, et al. International trends in the incidence of malignant melanoma 1953–2008-are recent generations at higher or lower risk? Int J Cancer. 2013;132(2):385–400. https://doi.org/10.1002/ijc.27616.

CAS  Article  PubMed  Google Scholar 

Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer. 2016;16(6):345–58. https://doi.org/10.1038/nrc.2016.37.

CAS  Article  PubMed  Google Scholar 

Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol Mech Dis. 2014;9(1):239–71. https://doi.org/10.1146/annurev-pathol-012513-104658.

CAS  Article  Google Scholar 

Viros A, et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 2008;5(6): e120. https://doi.org/10.1371/journal.pmed.0050120.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Bandarchi B, Jabbari CA, Vedadi A, Navab R. Molecular biology of normal melanocytes and melanoma cells. J Clin Pathol. 2013;66(8):644–8. https://doi.org/10.1136/jclinpath-2013-201471.

CAS  Article  PubMed  Google Scholar 

Hussein MR. Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues. J Clin Pathol. 2005;58(5):453–6. https://doi.org/10.1136/jcp.2004.019422.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Balch CM, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206. https://doi.org/10.1200/JCO.2009.23.4799.

Article  PubMed  PubMed Central  Google Scholar 

Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet. 2014;383(9919):816–27. https://doi.org/10.1016/S0140-6736(13)60802-8.

CAS  Article  PubMed  Google Scholar 

Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2011;65(5):1032–47. https://doi.org/10.1016/j.jaad.2011.04.031.

Article  PubMed  Google Scholar 

Scolyer RA, Long GV, Thompson JF. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Mol Oncol. 2011;5(2):124–36. https://doi.org/10.1016/j.molonc.2011.03.002.

Article  PubMed  PubMed Central  Google Scholar 

Smoller BR. Histologic criteria for diagnosing primary cutaneous malignant melanoma. Mod Pathol. 2006;19(S2):S34–40. https://doi.org/10.1038/modpathol.3800508.

Article  PubMed  Google Scholar 

Le Clair MZ, Cockburn MG. Tanning bed use and melanoma: establishing risk and improving prevention interventions. Prev Med Reports. 2016;3:139–44. https://doi.org/10.1016/j.pmedr.2015.11.016.

Article  Google Scholar 

Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo (Brooklyn) 2014;28(6):1005–11 [Online]. https://iv.iiarjournals.org/content/28/6/1005.short.

Liu Y, Sheikh MS. Melanoma: molecular pathogenesis and therapeutic management. Mol Cell Pharmacol 2014;6(3):228 [Online]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346328/.

Reddy BY, Miller DM, Tsao H. Somatic driver mutations in melanoma. Cancer. 2017;123(S11):2104–17. https://doi.org/10.1002/cncr.30593.

Article  PubMed  Google Scholar 

Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458(7239):719–24. https://doi.org/10.1038/nature07943.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Akbani R, et al. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681–96. https://doi.org/10.1016/j.cell.2015.05.044.

CAS  Article  Google Scholar 

Hawryluk EB, Tsao H. Melanoma: clinical features and genomic insights. Cold Spring Harb Perspect Med. 2014;4(9):a015388–a015388. https://doi.org/10.1101/cshperspect.a015388.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Franken MG, Leeneman B, Gheorghe M, Uyl-de Groot CA, Haanen JBAG, van Baal PHM. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. Eur J Cancer 2019;123:58–71 [Online]. https://www.sciencedirect.com/science/article/pii/S0959804919307257.

Tran KB, Buchanan CM, Shepherd PR. Evolution of molecular targets in melanoma treatment. Curr Pharm Des 2020;26(4):396–414 [Online]. https://www.ingentaconnect.com/content/ben/cpd/2020/00000026/00000004/art00002.

Prieto PA et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18(7):2039–47 [Online]. https://clincancerres.aacrjournals.org/content/18/7/2039.short.

Robert C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364(26):2517–26 [Online]. https://www.nejm.org/doi/full/10.1056/Nejmoa1104621.

Kaufman HL et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013;10(10):588–98 [Online]. https://www.nature.com/articles/nrclinonc.2013.153.

Weber JS, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84. https://doi.org/10.1016/S1470-2045(15)70076-8.

CAS  Article  PubMed  Google Scholar 

Ascierto PA, et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–60. https://doi.org/10.1016/S1470-2045(16)30122-X.

CAS  Article  PubMed  Google Scholar 

Christofi T, Baritaki S, Falzone L, Libra M, Zaravinos A. Current perspectives in cancer immunotherapy. Cancers (Basel). 2019;11(10):1472. https://doi.org/10.3390/cancers11101472.

CAS  Article  Google Scholar 

Robert C, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–51. https://doi.org/10.1016/S1470-2045(19)30388-2.

CAS  Article  PubMed  Google Scholar 

Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–62. https://doi.org/10.1016/S0140-6736(17)31601-X.

CAS  Article  PubMed  Google Scholar 

Weber J, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35. https://doi.org/10.1056/NEJMoa1709030.

CAS  Article  PubMed  Google Scholar 

Eggermont AMM, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–801. https://doi.org/10.1056/NEJMoa1802357.

CAS  Article  PubMed  Google Scholar 

Larkin J, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46. https://doi.org/10.1056/NEJMoa1910836.

CAS  Article  PubMed  Google Scholar 

Ascierto PA, et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated wit